De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Progyny Beheer

Beheer criteriumcontroles 4/4

De CEO Progyny's is Pete Anevski, benoemd in Jan2022, heeft een ambtstermijn van 2.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.09M, bestaande uit 45.7% salaris en 54.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.16% van de aandelen van het bedrijf, ter waarde $ 2.45M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 7.6 jaar.

Belangrijke informatie

Pete Anevski

Algemeen directeur

US$1.1m

Totale compensatie

Percentage CEO-salaris	45.7%
Dienstverband CEO	2.8yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	2.8yrs
Gemiddelde ambtstermijn bestuur	7.6yrs

Recente managementupdates

Recent updates

Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors

Sep 29

Progyny: Downgrading As Uncertainties Increase

Aug 15

Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

Aug 11

There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Aug 06

Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

May 06

When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Jan 25

Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue

Dec 12

Is It Time To Consider Buying Progyny, Inc. (NASDAQ:PGNY)?

Oct 18

Analyse CEO-vergoeding

Hoe is Pete Anevski's beloning veranderd ten opzichte van Progyny's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$63m
Mar 31 2024	n/a	n/a	US$61m
Dec 31 2023	US$1m	US$500k	US$62m
Sep 30 2023	n/a	n/a	US$52m
Jun 30 2023	n/a	n/a	US$49m
Mar 31 2023	n/a	n/a	US$43m
Dec 31 2022	US$69m	US$500k	US$30m
Sep 30 2022	n/a	n/a	US$42m
Jun 30 2022	n/a	n/a	US$46m
Mar 31 2022	n/a	n/a	US$56m
Dec 31 2021	US$786k	US$425k	US$66m
Sep 30 2021	n/a	n/a	US$90m
Jun 30 2021	n/a	n/a	US$78m
Mar 31 2021	n/a	n/a	US$58m
Dec 31 2020	US$910k	US$425k	US$46m
Sep 30 2020	n/a	n/a	US$3m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$5m
Dec 31 2019	US$5m	US$375k	-US$9m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	US$1m
Mar 31 2019	n/a	n/a	-US$4m
Dec 31 2018	US$682k	US$325k	-US$6m

Compensatie versus markt: De totale vergoeding ($USD 1.09M ) Pete } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Pete is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Pete Anevski (57 yo)

2.8yrs

Tenure

US$1,093,512

Compensatie

Mr. Peter Anevski, also known as Pete, has been Chief Executive Officer and Director of Progyny, Inc. since January 2022 and had been its President since June 2019 until December 31, 2021 and was its Chief...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
David Schlanger	Executive Chairman	7.6yrs	US$513.57k	0.055% $ 806.1k
Peter Anevski	CEO & Director	2.8yrs	US$1.09m	0.16% $ 2.4m
Michael Sturmer	President	2.8yrs	US$1.49m	0.073% $ 1.1m
Mark Livingston	Chief Financial Officer	4.1yrs	US$1.40m	0.049% $ 724.3k
Allison Swartz	Executive VP	1.9yrs	US$546.22k	0.018% $ 271.1k
Steven Leist	Chief Technology Officer	less than a year	geen gegevens	geen gegevens
James Hart	Vice President of Investor Relations	no data	geen gegevens	geen gegevens
Risa Fisher	Chief Marketing Officer	no data	geen gegevens	geen gegevens
Cassandra Pratt	Chief Human Resources Officer	no data	geen gegevens	geen gegevens
Julie Stadlbauer	Chief Business Development Officer	2.8yrs	geen gegevens	geen gegevens
Janet Choi	Member of the Medical Advisory Board & Chief Medical Officer	1.5yrs	geen gegevens	geen gegevens
Arielle Bogorad	Senior Vice President of Employer Market Strategy	2.4yrs	geen gegevens	geen gegevens

2.8yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PGNY wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Schlanger	Executive Chairman	7.6yrs	US$513.57k	0.055% $ 806.1k
Peter Anevski	CEO & Director	2.8yrs	US$1.09m	0.16% $ 2.4m
Janet Choi	Member of the Medical Advisory Board & Chief Medical Officer	no data	geen gegevens	geen gegevens
Norman Payson	Independent Director	7.8yrs	US$567.30k	0.45% $ 6.6m
Fred Cohen	Independent Director	9.6yrs	US$583.35k	0.013% $ 197.8k
Beth Seidenberg	Lead Independent Director	14.4yrs	US$653.39k	0.29% $ 4.2m
Kevin Gordon	Independent Director	5yrs	US$518.30k	0.0069% $ 101.1k
Jeffrey Park	Independent Director	5yrs	US$606.88k	0.013% $ 197.8k
Alan Copperman	Member of the Medical Advisory Board	no data	geen gegevens	geen gegevens
Barry Behr	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Brad Kolb	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Gerard Letterie	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens

7.6yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PGNY wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.6 jaar).

Progyny Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

President notifies of intention to sell stock

Progyny, Inc., Annual General Meeting, May 23, 2024

Executive Chairman exercised options and sold US$2.4m worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Progyny, Inc. Announces Executive Appointments

Recent updates

Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors

Investor sentiment deteriorates as stock falls 29%

Price target decreased by 14% to US$26.13

Progyny: Downgrading As Uncertainties Increase

Consensus EPS estimates fall by 16%

Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

Progyny, Inc. Updates Earnings Guidance for the Full Year Ending December 31, 2024

Progyny, Inc. to Report Q2, 2024 Results on Aug 06, 2024

At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

President notifies of intention to sell stock

Progyny: Recent Stock Decline Provides Buying Opportunity

Progyny, Inc. (NasdaqGS:PGNY) acquired Apryl GmbH.

Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall

Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore

Progyny: No Change To Long-Term Outlook

Progyny, Inc. (NasdaqGS:PGNY) announces an Equity Buyback for $100 million worth of its shares.

Price target decreased by 7.1% to US$43.40

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Progyny, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Progyny, Inc. to Report Q1, 2024 Results on May 09, 2024

Progyny, Inc., Annual General Meeting, May 23, 2024

Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Executive Chairman exercised options and sold US$2.4m worth of stock

Progyny: Long-Term Outlook Remains Positive, Reiterate Buy

Progyny: Long-Term Thesis Still Intact

Chief Financial Officer notifies of intention to sell stock

Progyny, Inc. (NasdaqGS:PGNY) announces an Equity Buyback for $100 million worth of its shares.

Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Progyny, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Period Ending December 31, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Progyny, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Chief Financial Officer notifies of intention to sell stock

Progyny, Inc. Announces Executive Appointments

Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Executive Chairman exercised options and sold US$5.5m worth of stock

Executive Chairman notifies of intention to sell stock

Executive Chairman notifies of intention to sell stock

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Chief Financial Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Progyny, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Consensus EPS estimates increase by 28%

There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Progyny, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Executive Chairman exercised options and sold US$4.0m worth of stock

Executive Chairman exercised options and sold US$714k worth of stock

Executive Chairman exercised options and sold US$3.1m worth of stock

Insider recently sold US$54k worth of stock

Consensus EPS estimates increase by 54%

CEO & Director notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Progyny, Inc. Raises Financial Guidance for the Full Year Ending December 31, 2023

Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

CEO & Director exercised options and sold US$318k worth of stock

Consensus EPS estimates fall by 17%

Executive Chairman exercised options and sold US$4.0m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Progyny, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Investor sentiment deteriorates as stock falls 16%

Executive Chairman exercised options and sold US$3.5m worth of stock

When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Price target decreased to US$48.57

Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue